Rojo F - Search Results

1

miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer.

Cabello P, Torres-Ruiz S, Adam-Artigues A, Forés-Martos J, Martínez MT, Hernando C, Zazo S, Madoz-Gúrpide J, Rovira A, Burgués O, Rojo F, Albanell J, Lluch A, Bermejo B, Cejalvo JM, Eroles P. Cabello P, et al. Among authors: rojo f. Cancers (Basel). 2023 Apr 4;15(7):2138. doi: 10.3390/cancers15072138. Cancers (Basel). 2023. PMID: 37046799 Free PMC article.

2

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.

Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Molina MA, et al. Among authors: rojo f. Cancer Res. 2001 Jun 15;61(12):4744-9. Cancer Res. 2001. PMID: 11406546

3

Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839.

Albanell J, Rojo F, Baselga J. Albanell J, et al. Among authors: rojo f. Semin Oncol. 2001 Oct;28(5 Suppl 16):56-66. doi: 10.1016/s0093-7754(01)90283-0. Semin Oncol. 2001. PMID: 11706397 Review.

4

NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer.

Molina MA, Sáez R, Ramsey EE, Garcia-Barchino MJ, Rojo F, Evans AJ, Albanell J, Keenan EJ, Lluch A, García-Conde J, Baselga J, Clinton GM. Molina MA, et al. Among authors: rojo f. Clin Cancer Res. 2002 Feb;8(2):347-53. Clin Cancer Res. 2002. PMID: 11839648

5

ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.

Anido J, Matar P, Albanell J, Guzmán M, Rojo F, Arribas J, Averbuch S, Baselga J. Anido J, et al. Among authors: rojo f. Clin Cancer Res. 2003 Apr;9(4):1274-83. Clin Cancer Res. 2003. PMID: 12684395

6

Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.

Baselga J, Albanell J, Ruiz A, Lluch A, Gascón P, Guillém V, González S, Sauleda S, Marimón I, Tabernero JM, Koehler MT, Rojo F. Baselga J, et al. Among authors: rojo f. J Clin Oncol. 2005 Aug 10;23(23):5323-33. doi: 10.1200/JCO.2005.08.326. Epub 2005 Jun 6. J Clin Oncol. 2005. PMID: 15939921 Clinical Trial.

7

p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer.

Sáez R, Molina MA, Ramsey EE, Rojo F, Keenan EJ, Albanell J, Lluch A, García-Conde J, Baselga J, Clinton GM. Sáez R, et al. Among authors: rojo f. Clin Cancer Res. 2006 Jan 15;12(2):424-31. doi: 10.1158/1078-0432.CCR-05-1807. Clin Cancer Res. 2006. PMID: 16428482 Clinical Trial.

8

mTOR signalling in human cancer.

Albanell J, Dalmases A, Rovira A, Rojo F. Albanell J, et al. Among authors: rojo f. Clin Transl Oncol. 2007 Aug;9(8):484-93. doi: 10.1007/s12094-007-0092-6. Clin Transl Oncol. 2007. PMID: 17720651 Review.

9

Pharmacodynamics: biological activity of targeted therapies in clinical trials.

Rojo F, Dalmases A, Corominas JM, Albanell J. Rojo F, et al. Clin Transl Oncol. 2007 Oct;9(10):634-44. doi: 10.1007/s12094-007-0116-2. Clin Transl Oncol. 2007. PMID: 17974524 Review.

10

Genetic changes in small cell lung carcinoma.

Arriola E, Cañadas I, Arumí M, Rojo F, Rovira A, Albanell J. Arriola E, et al. Among authors: rojo f. Clin Transl Oncol. 2008 Apr;10(4):189-97. doi: 10.1007/s12094-008-0181-1. Clin Transl Oncol. 2008. PMID: 18411191 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

476 results

Search Page